Abstract
MK-0991 (L-743,872) is a potent antifungal agent featuring long half-life pharmacokinetics. The pharmacokinetics of MK-0991 administered intravenously to mice, rats, rhesus monkeys, and chimpanzees is presented. Unique to MK-0991 is its consistent cross-species performance. The range of values for the pharmacokinetic parameters were as follows: clearance, 0.26 to 0.51 ml/min/kg; half-life, 5.2 to 7.6 h; and distributive volume, 0.11 to 0.27 liters/kg. The level of protein binding of MK-0991 was determined to be 96% in mouse and human serum. The compound exhibited high affinities for human serum albumin and at least two lipid components. The rationale for the selection of MK-0991 as a drug development candidate was based on its two- to threefold superior pharmacokinetic performance in chimpanzees over the performance of an otherwise equivalent analog, L-733,560. Once-daily dosing for MK-0991 is indicated by a graphical comparison of levels in the circulations of chimpanzees and mice. In a study of the pharmacokinetics of MK-0991 in mouse tissue, the organs were assayed following intraperitoneal administration. The area under the concentration-versus-time curves (AUC) segregated the tissues into three exposure categories relative to plasma. The tissues with greater exposure than that for plasma were liver (16 times), kidney (3 times), and large intestine (2 times). The exposure for small intestine, lung, and spleen were equivalent to that for plasma. Organs with lower levels of exposure were the heart (0.3 times that for plasma), thigh (0.2 times), and brain (0.06 times). Kinetically, drug was cleared more slowly from all tissues than from plasma, indicating that terminal-phase equilibrium had not been achieved by 24 h. Thus, some measure of accumulation is predicted for all tissues. Single daily doses of MK-0991 should provide adequate systemic levels of fungicidal activity as a result of its long half-life pharmacokinetics, wide distribution, and slowly accumulating concentrations in tissue.
Full Text
The Full Text of this article is available as a PDF (192.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abruzzo G. K., Flattery A. M., Gill C. J., Kong L., Smith J. G., Krupa D., Pikounis V. B., Kropp H., Bartizal K. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1995 May;39(5):1077–1081. doi: 10.1128/aac.39.5.1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Abruzzo G. K., Flattery A. M., Gill C. J., Kong L., Smith J. G., Pikounis V. B., Balkovec J. M., Bouffard A. F., Dropinski J. F., Rosen H. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1997 Nov;41(11):2333–2338. doi: 10.1128/aac.41.11.2333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Balkovec J. M., Black R. M., Hammond M. L., Heck J. V., Zambias R. A., Abruzzo G., Bartizal K., Kropp H., Trainor C., Schwartz R. E. Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem. 1992 Jan;35(1):194–198. doi: 10.1021/jm00079a027. [DOI] [PubMed] [Google Scholar]
- Bartizal K., Abruzzo G., Trainor C., Krupa D., Nollstadt K., Schmatz D., Schwartz R., Hammond M., Balkovec J., Vanmiddlesworth F. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother. 1992 Aug;36(8):1648–1657. doi: 10.1128/aac.36.8.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bartizal K., Gill C. J., Abruzzo G. K., Flattery A. M., Kong L., Scott P. M., Smith J. G., Leighton C. E., Bouffard A., Dropinski J. F. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997 Nov;41(11):2326–2332. doi: 10.1128/aac.41.11.2326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
- Bouffard F. A., Zambias R. A., Dropinski J. F., Balkovec J. M., Hammond M. L., Abruzzo G. K., Bartizal K. F., Marrinan J. A., Kurtz M. B., McFadden D. C. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 1994 Jan 21;37(2):222–225. doi: 10.1021/jm00028a003. [DOI] [PubMed] [Google Scholar]
- Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
- Brazzell R. K., Park Y. H., Wooldridge C. B., McCue B., Barker R., Couch R., York B. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos. 1990 Jul-Aug;18(4):435–440. [PubMed] [Google Scholar]
- Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
- Lee J. W., Kelly P., Lecciones J., Coleman D., Gordee R., Pizzo P. A., Walsh T. J. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother. 1990 Nov;34(11):2240–2245. doi: 10.1128/aac.34.11.2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rouse M. S., Tallan B. M., Steckelberg J. M., Henry N. K., Wilson W. R. Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 1992 Jan;36(1):56–58. doi: 10.1128/aac.36.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmatz D. M., Abruzzo G., Powles M. A., McFadden D. C., Balkovec J. M., Black R. M., Nollstadt K., Bartizal K. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot (Tokyo) 1992 Dec;45(12):1886–1891. doi: 10.7164/antibiotics.45.1886. [DOI] [PubMed] [Google Scholar]
- Schmatz D. M., Powles M. A., McFadden D. C., Pittarelli L., Balkovec J., Hammond M., Zambias R., Liberator P., Anderson J. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob Agents Chemother. 1992 Sep;36(9):1964–1970. doi: 10.1128/aac.36.9.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwartz R. E., Sesin D. F., Joshua H., Wilson K. E., Kempf A. J., Goklen K. A., Kuehner D., Gailliot P., Gleason C., White R. Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J Antibiot (Tokyo) 1992 Dec;45(12):1853–1866. doi: 10.7164/antibiotics.45.1853. [DOI] [PubMed] [Google Scholar]
- Sundelof J. G., Hajdu R., Cleare W. J., Onishi J., Kropp H. Pharmacokinetics of L-671,329 in rhesus monkeys and DBA/2 mice. Antimicrob Agents Chemother. 1992 Mar;36(3):607–610. doi: 10.1128/aac.36.3.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walsh T. J., Lee J. W., Roilides E., Francis P., Bacher J., Lyman C. A., Pizzo P. A. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S139–S147. doi: 10.1093/clinids/14.supplement_1.s139. [DOI] [PubMed] [Google Scholar]